Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-659: Pembrolizumab + Chemo in Advanced Gastric Cancer
NCT03382600Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2018
- Primary completion
- May 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab in gastric cancer (GC) and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Merck & Co. Primary endpoint: Objective Response Rate at 36 months. Started Mar 2018; status: completed.
02
Drugs
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT03382600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03382600.